Impaired Ca2+ signaling attenuates P2X receptor-mediated vasoconstriction of afferent arterioles in angiotensin II hypertension

Hypertension. 2005 Sep;46(3):562-8. doi: 10.1161/01.HYP.0000179584.39937.41. Epub 2005 Aug 22.

Abstract

This study tested the hypothesis that afferent arteriolar responses to purinoceptor activation are attenuated, and Ca2+ signaling mechanisms are responsible for the blunted preglomerular vascular reactivity in angiotensin II (Ang II) hypertension. Experiments determined the effects of ATP, the P2X1 agonist beta,gamma-methylene ATP or the P2Y agonist UTP on arteriolar diameter using the juxtamedullary nephron technique and on renal myocyte intracellular Ca2+ concentration ([Ca2+]i) using single cell fluorescence microscopy. Six or 13 days of Ang II infusion significantly attenuated the vasoconstrictor responses to ATP and beta,gamma-methylene ATP (P<0.05). During exposure to ATP (1, 10, and 100 micromol/L), afferent diameter declined by 17+/-2%, 29+/-3%, and 30+/-2% in normal control rats and 8+/-3%, 7+/-3%, and 22+/-3% in kidneys of Ang II-infused rats (13 days). Renal myocyte intracellular calcium responses to ATP or beta,gamma-methylene ATP were also decreased in Ang II hypertensive rats. In myocytes of control rats, peak increases in [Ca2+]i averaged 107+/-21, 170+/-38, and 478+/-79 nmol/L at ATP concentrations of 1, 10, and 100 micromol/L, respectively. Ang II infusion for 13 days decreased the peak responses to ATP (1, 10, and 100 micromol/L) to 65+/-13, 102+/-20, and 367+/-73 nmol/L, respectively. The peak increases in [Ca2+]i in response to beta,gamma-methylene ATP were also reduced in Ang II hypertensive rats. However, angiotensin hypertension did not change the UTP-mediated vasoconstrictor responses or the myocyte calcium responses to UTP. These results indicate that the impaired autoregulatory response observed in Ang II-dependent hypertension can be attributed to impairment of P2X1 receptor-mediated signal transduction.

Publication types

  • Research Support, N.I.H., Extramural
  • Research Support, Non-U.S. Gov't
  • Research Support, U.S. Gov't, P.H.S.

MeSH terms

  • Adenosine / pharmacology
  • Adenosine Triphosphate / analogs & derivatives
  • Adenosine Triphosphate / pharmacology
  • Angiotensin II*
  • Animals
  • Arterioles / drug effects
  • Arterioles / physiopathology*
  • Blood Pressure
  • Calcium / metabolism
  • Calcium Signaling*
  • Homeostasis
  • Hypertension / chemically induced
  • Hypertension / physiopathology*
  • Intracellular Membranes / metabolism
  • Kidney / blood supply*
  • Kidney / metabolism
  • Male
  • Microcirculation
  • Muscle, Smooth, Vascular / metabolism
  • Myocytes, Smooth Muscle / metabolism
  • Purinergic P2 Receptor Agonists
  • Rats
  • Rats, Sprague-Dawley
  • Receptor, Adenosine A1 / drug effects
  • Receptor, Adenosine A1 / metabolism
  • Receptors, Purinergic P2 / drug effects
  • Receptors, Purinergic P2 / metabolism*
  • Receptors, Purinergic P2X
  • Uridine Triphosphate / pharmacology
  • Vasoconstriction*

Substances

  • Purinergic P2 Receptor Agonists
  • Receptor, Adenosine A1
  • Receptors, Purinergic P2
  • Receptors, Purinergic P2X
  • Angiotensin II
  • 5'-adenylyl (beta,gamma-methylene)diphosphonate
  • Adenosine Triphosphate
  • Adenosine
  • Calcium
  • Uridine Triphosphate